Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $405.00 price target on United Therapeutics Corp. (NASDAQ:UTHR), representing significant upside potential from the current price of $309.72. According to InvestingPro analysis, the company maintains excellent financial health with an impressive 88.98% gross profit margin and trades at an attractive P/E ratio of 11.2.
The research firm maintained its positive outlook on the pharmaceutical company, citing the upcoming TETON trials as a potential catalyst for the stock.
Cantor Fitzgerald believes the TETON trials have "a real shot at succeeding" and that the trial design should give Tyvaso, United Therapeutics’ inhaled treatment, "a good chance at success."
The firm noted that the benchmark for success—"a 70-80 mL placebo-adjusted FVC treatment effect"—appears to be "attainable" based on their analysis.
Cantor Fitzgerald also suggested that the potential commercial opportunity for Tyvaso in idiopathic pulmonary fibrosis (IPF) remains "under-appreciated" by the market.
In other recent news, United Therapeutics Corporation reported its second-quarter earnings for 2025, which showed a slight miss in both earnings per share (EPS) and revenue forecasts. The company posted an EPS of $6.41, missing the anticipated $7.35, and revenue reached $799 million, just below the forecasted $804.98 million. Additionally, United Therapeutics announced a $1 billion accelerated share repurchase program, entering into agreements with Citibank, N.A. for the buyback. UBS raised its price target for United Therapeutics to $415 from $385 while maintaining a Buy rating, highlighting a favorable risk/reward profile. Meanwhile, H.C. Wainwright lowered its price target to $400 from $425 due to concerns about increased competition for the Tyvaso treatment. The recent approval of Yutrepia is expected to impact Tyvaso’s market penetration in PAH and PH-ILD indications. These developments reflect ongoing strategic and competitive challenges for United Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.